ZIM Laboratories

ZIM Laboratories EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ZIM Laboratories (ZIMLAB.NS) as of Oct 24, 2026 is 188.70 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 401.59 M INR — a change of -53.01% (lower).

EBITDA

188.70 MINR

YoY

-53.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ZIM Laboratories is 2026 188.70 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ZIM Laboratories was 2025 401.59 M INR. It decreases by -53.01% lower compared to the previous year.

The ZIM Laboratories EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
315.57 M INR
Jan 1, 2020
102.01 M INR
Jan 1, 2021
405.13 M INR
Jan 1, 2022
384.90 M INR
Jan 1, 2023
537.90 M INR
Jan 1, 2024
463.89 M INR
Jan 1, 2025
401.59 M INR
Jan 1, 2026
188.70 M INR
The ZIM Laboratories EBITDA history
YEAREBITDAYoY
188.70 MINR-53.01%
401.59 MINR-13.43%
463.89 MINR-13.76%
537.90 MINR+39.75%
384.90 MINR-4.99%
405.13 MINR+297.16%
102.01 MINR-67.68%
315.57 MINR+15.04%
274.32 MINR+15.23%
238.05 MINR+9.50%
217.40 MINR+47.59%
147.30 MINR-74.58%
579.48 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZIM Laboratories Stock analysis

What does ZIM Laboratories do? Zim Laboratories Ltd. develops, manufactures, and supplies oral solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) across therapeutic segments including central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology, and vitamins, minerals, and dietary supplements. The company's technological capabilities focus on drug release modification, solubility and stability enhancement, taste masking, and dosage form transformation. Its product offerings include finished formulations such as tablets, capsules, oral thin films, granules, pellets, taste-masked powders, and dry suspensions, alongside pre-formulation intermediates. The firm generates revenue through the supply of these pharmaceutical products to healthcare providers and distributors within the Indian market. The company's delivery solutions encompass product conceptualization, development, registration filing, manufacturing, and supply, targeting various therapeutic segments. Its differentiated generic formulations cater to specific medical needs, with a focus on innovation in drug delivery systems. Zim Laboratories Ltd. serves the Indian pharmaceutical market, supplying both finished products and pre-formulation intermediates to meet the demands of healthcare institutions and retail pharmacies. Zim Laboratories Ltd. operates as a pharmaceutical company based in Nagpur, Maharashtra, with 525 full-time employees. It develops and manufactures generic pharmaceutical products including oral solid dosage forms and pre-formulation intermediates. The company's revenue streams come from the sale of these products to customers in the healthcare sector, particularly within the Indian market, leveraging its technological capabilities in drug formulation and delivery. ZIM Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZIM Laboratories stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ZIM Laboratories is 188.70 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ZIM Laboratories changed from 401.59 M INR to 188.70 M INR, representing a -53.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ZIM Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ZIM Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ZIM Laboratories

All Key Metrics — ZIM Laboratories